Here's Why Bristol Myers Squibb Can't Miss Out on Aurinia Pharmaceuticals

Here's Why Bristol Myers Squibb Can't Miss Out on Aurinia Pharmaceuticals

Source: 
Motley Fool
snippet: 
  • Biopharma merger agreements tend to happen fast once news of talks leaks to the public.
  • Aurinia Pharmaceuticals has yet to get a formal bid from any of its rumored suitors.
  • This key issue might be the reason for the delay.